Although biotech companies often raise eyebrows by plunging ahead without compelling clinical data or a clear market advantage, Hoechst Marion Roussel AG last week demonstrated that big pharma is not immune to the phenomenon.

HMR said it plans to seek a label expansion for its Refludan lepirudin direct thrombin inhibitor to treat unstable angina in addition to its existing indication for heparin-induced thrombocytopenia (HIT).